AbbVie (ABBV) and Biogen (BIIB) on Torvanta's measures: ABBV grades higher on 2 of the 4 factor families and BIIB on 2.
| ABBV | BIIB | |
|---|---|---|
| Value grade | C | B |
| Growth grade | B+ | D |
| Profitability grade | A- | n/a |
| Momentum grade | B | B+ |
| Market value | $504.4B | n/a |
| P/E (trailing) | 80.6x | n/a |
| Forward P/E (Torvanta model estimate) | Subscribers | Subscribers |
| Revenue, last 12 months | $64.4B | $9.9B |
| Revenue growth (y/y) | +10% | n/a |
| Operating margin | 26.2% | 23.2% |
| Return on invested capital | n/a | n/a |
| Free-cash-flow yield | 3.6% | 8.4% |
| Total return, 1 year | +28.8% | +63.5% |
| Total return, 3 years | +113.0% | -13.2% |
Full ABBV analysis · Full BIIB analysis
AbbVie (ABBV) and Biogen (BIIB) on Torvanta's measures: ABBV grades higher on 2 of the 4 factor families and BIIB on 2. Which fits an investor depends on their goals; this is research, not a recommendation. Subscribers see where the model ranks each and its expected return.
On trailing earnings ABBV trades at 80.6x and BIIB at n/a; their value grades are C and B against their sectors.
Subscribers get a rating, a fair value estimate, a 12-month target and a risk read for every S&P 500 company, Torvanta's earnings estimates, and three model portfolios (Active, Adaptive and Patient) with every trade sized and explained. A free account includes 3 full Stock Analyst reports a month.
See plans Or get the free weekly newsletterTorvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.
All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer